Revive TherapeuticsRVVTF

13F holders, Q4 2024 (December 31)
1holders
1new positions
1sold out
$0.01avg. 13F price*

At the end of Q4 2024, 1 institutions reported holding Revive Therapeutics Ltd. (RVVTF) in their 13F filings, unchanged from Q3 2024. 1 opened new positions and 1 sold out. The largest holder was FineMark National Bank & Trust ($61).

Company
Revive Therapeutics Ltd.
CUSIP
761516103
Latest filing quarter
Q1 2026

History

Number of 13F holders

0123 Q1 2024: 3Q1 2024Q2 2024: 2Q2 2024Q3 2024: 1Q3 2024Q4 2024: 1Q4 2024Q1 2025: 1Q1 2025Q2 2025: 1Q2 2025Q3 2025: 2Q3 2025Q4 2025: 2Q4 2025Q1 2026: 1Q1 2026

Total Exit/New Position Q3 2024 → Q4 2024

InstitutionsTotal Value
New Positions1$61
Exits1$158

All 13F filers, Q3 2024 → Q4 2024: 10,345 shares bought and 25,000 shares sold, net −14,655 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 1 holders

FineMark National Bank & Trust 0.00% New 10,345 $61

"% of holder's portfolio" is RVVTF's weight in each manager's 13F, not the share of Revive Therapeutics Ltd. the manager owns.